EUVIMEDEUVIMED entdecken
Open Access

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacy

Tyler C Detomasi iD, Gilles Degotte iD, Sijie Huang iD, Rahul K Suryawanshi iD, Amy Diallo, Luca Lizzadro, Francisco J Zapatero-Belinchón, Taha Y Taha iD, Jiapeng Li iD, Alicia L Richards, Eric R Hantz iD, Zain Alam und 21 weitere

Science Advances · 25.04.2025 · 11 (17)

DOI: 10.1126/sciadv.adt7836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 25.04.2025. Verfasst von Tyler C Detomasi und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, Coronavirus 3C Proteases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main protease (M Pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a validated drug target. Starting with a lead-like dihydrouracil chemotype identified in a large-library docking campaign, we improved M Pro inhibition >1000-fold by engaging additional M Pro subsites and using a latent electrophile to engage Cys 145 . Advanced leads from this series show pan-coronavirus antiviral activity, low clearance in mice, and for AVI-4773 , a rapid reduction in viral titers >1,000,000 after just three doses. Both compounds are well distributed in mouse tissues, including brain, where concentrations >1000× the 90% effective concentration are observed 8 hours after oral dosing for AVI-4773 . AVI-4516 shows minimal inhibition of major cytochrome P450s and human proteases. AVI-4516 also exhibits synergy with the RNA-dependent RNA polymerase inhibitor, molnupiravir, in cellular infection models. Related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus. The properties of this chemotype are differentiated from existing clinical and preclinical M Pro inhibitors and will advance therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentCoronavirus 3C ProteasesProtease InhibitorsAnimalsMiceHumansDrug DiscoveryMolecular Docking SimulationCOVID-19HydroxylaminesCytidineLactamsLeucineNitrilesProline

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsmolnupiravirnirmatrelvirHydroxylaminesCytidineLactamsLeucineNitriles

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.
  • Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
  • Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.
  • Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
  • Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.

ORCID-Profile: Tyler C Detomasi, Gilles Degotte, Sijie Huang, Rahul K Suryawanshi, Taha Y Taha, Jiapeng Li, Eric R Hantz, Mauricio Montano, James R Partridge, Galen J Correy, Annemarie F Charvat, Isabella S Glenn, Julia Rosecrans, Judd F Hultquist, Michelle R Arkin, R Jeffrey Neitz, Danielle L Swaney, Nevan J Krogan, Brian K Shoichet, Kliment A Verba, Melanie Ott, Adam R Renslo, Charles S Craik

Förderung

  • NIAID NIH HHS

Zitieren

APA

Detomasi, T. C., Degotte, G., Huang, S., Suryawanshi, R. K., Diallo, A., Lizzadro, L., Zapatero-Belinchón, F. J., Taha, T. Y., Li, J., Richards, A. L., Hantz, E. R., Alam, Z., Montano, M., McCavitt-Malvido, M., Gumpena, R., Partridge, J. R., Correy, G. J., Matsui, Y., Charvat, A. F., …, & Craik, C. S. (2025). Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacy. Science Advances, 11(17). https://doi.org/10.1126/sciadv.adt7836

Vancouver

Detomasi TC, Degotte G, Huang S, Suryawanshi RK, Diallo A, Lizzadro L, et al. Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacy. Science Advances. 2025;11(17). doi:10.1126/sciadv.adt7836

BibTeX
@article{Detomasi2025,
  author = {Detomasi, Tyler C and Degotte, Gilles and Huang, Sijie and Suryawanshi, Rahul K and Diallo, Amy and Lizzadro, Luca and Zapatero-Belinchón, Francisco J and Taha, Taha Y and Li, Jiapeng and Richards, Alicia L and Hantz, Eric R and Alam, Zain and Montano, Mauricio and McCavitt-Malvido, Maria and Gumpena, Rajesh and Partridge, James R and Correy, Galen J and Matsui, Yusuke and Charvat, Annemarie F and Glenn, Isabella S and Rosecrans, Julia and Revalde, Jezrael L and Anderson, Dashiell and Hultquist, Judd F and Arkin, Michelle R and Neitz, R Jeffrey and Swaney, Danielle L and Krogan, Nevan J and Shoichet, Brian K and Verba, Kliment A and Ott, Melanie and Renslo, Adam R and Craik, Charles S},
  title = {Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacy},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {17},
  doi = {10.1126/sciadv.adt7836}
}
Kostenlos starten →